View Filing Data

Property, Plant and Equipment [Abstract]

PREPAID EXPENSES

Prepaid expenses consisted of the following as of September 30, 2012 and December 31, 2011:

	2012		2011
Insurance	$	7,257	$	5,937
Website maintenance		0		17,500
Rent		5,049		0
Consulting		31,627		91,811
Employee advances		959		694
Advertising		0		3,090
Total prepaid expenses	$	44,892	$	119,032

PROPERTY AND EQUIPMENT

9 Months Ended

Sep. 30, 2012

PROPERTY AND EQUIPMENT

The Company owned equipment recorded at cost which consisted of the following as of September 30, 2012 and December 31, 2011:

	2012			2011
Computer equipment	$	22,360		$	20,130
Furniture and fixtures		11,088			11,088
Subtotal		33,448			31,218
Accumulated depreciation		(11,381	)		(7,287	)
Property and equipment, net	$	22,067		$	23,931

Depreciation expense was $4,094 and $1,359 for the nine months ended September 30, 2012 and 2011, respectively.

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

WEBSITE DEVELOPMENT COSTS

9 Months Ended

Sep. 30, 2012

WEBSITE DEVELOPMENT COSTS

The Company has capitalized costs in developing their website and web-based products, which consisted of the following as of September 30, 2012 and December 31, 2011:

	2012			2011
OptimizeRx web development	$	154,133		$	154,133
SampleMD web development		602,517			553,877
Subtotal, web development costs		756,650			708,010
Accumulated amortization		(278,393	)		(183,429	)
Impairment		(59,083	)		(59,083	)
Web development costs, net	$	419,174		$	465,498

The Company began amortizing the OptimizeRx website costs, using the straight-line method over the estimated useful life of 5 years, once it was put into service in December of 2007. During the year ended December 31, 2009, the Company began a new web-based project and the related programming and development costs have been capitalized for the SampleMD website. The project was completed in mid-December 2010 and no amortization was recorded in 2010. Amortization began on the straight-line method in January 2011 over the period of five years. Although the Project was completed in mid-December, the Company continues to enhance and upgrade the website. Monthly payments for these upgrades and enhancements have been capitalized and amortization was started by quarter in 2011 and continues in 2012. The Company determined that the original OptimizeRx website was no longer useful so the remaining unamortized balance of $59,083 was impaired as of December 31, 2010.

Amortization expense was $94,964 and $47,761 for the nine months ended September 30, 2012 and 2011, respectively.

PATENT RIGHTS AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

PATENT RIGHTS AND INTANGIBLE ASSETS

On April 26, 2010, the Company acquired from an officer and shareholder the technical contributions and assignment of all exclusive rights to and for the SampleMD patent currently in process in exchange for 300,000 shares of common stock to be granted at the discretion of the seller in addition to 200,000 stock options valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party.

The Company has capitalized costs in purchasing the SampleMD patent, which consisted of the following as of September 30, 2012 and December 31, 2011:

	2012			2011
Patent rights and intangible assets	$	930,000		$	930,000
Accumulated amortization		(123,088	)		(82,059	)
Patent rights and intangible assets, net	$	806,912		$	847,941

The Company began amortizing the patent, using the straight-line method over the estimated useful life of 17 years, once it was put into service in July 2010. Amortization expense was $41,029 and $41,029 for the nine months ended September 30, 2012 and 2011, respectively.

ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2012

Deferred Revenue Disclosure [Abstract]

ACCRUED EXPENSES

Accrued expenses consisted of the following as of September 30, 2012 and December 31, 2011:

	2012		2011
Accrued payroll taxes	$	0	$	0
Accrued bonuses		0		60,000
Accrued audit fees		0		6,000
Total accrued expenses	$	0	$	66,000

DEFERRED REVENUE

9 Months Ended

Sep. 30, 2012

DEFERRED REVENUE

The Company has signed several contracts with customers for coupon redemptions on their website. The payments are not taken into revenue until the end user redeems the coupon. The redemptions are tracked via their website and revenues are recorded as the coupons are redeemed. Additionally, customer setup contracts that have been paid in full are deferred until the Company has completed the obligations of the contacts. Deferred revenue was $311,774 and $330,605 as of September 30, 2012 and December 31, 2011, respectively.

NOTE PAYABLE

9 Months Ended

Sep. 30, 2012

NOTE PAYABLE

On October 5, 2010, the Company issued a secured promissory note of $1,000,000 to an investor. The note accrues interest at 6% per annum, compounded on April and October each year and will be paid at the earliest of September 12, 2012 or earlier at the Company’s option. No principal or interest payments are required until the maturity date. Accrued interest was $15,000 as of December 31, 2010. The terms of the note also granted 1,000,000 stock warrants and 1,000,000 contingent stock warrants in connection with the financing. The non-contingent warrants were valued at $1,007,992 with $1,000,000 recorded as debt discount and $7,992 recorded as interest expense in the December 31, 2010 year. The Company analyzed the assumptions associated with the contingent warrants and determined that the performance objectives were not likely to occur in 2011. Therefore, no value was recorded for the contingent warrants. The debt discount derived from the warrant valuation of $1,000,000 was being amortized over the life of the loan using the straight-line method and charged to interest expense.

On September 16, 2011, the Company entered into a Termination Agreement, in conjunction with a Securities Purchase Agreement with another investor. Under the Termination Agreement, the Company paid off the $1,000,000 promissory note, plus all accrued interest to date. Upon payment of the note, the contingent stock warrants obligation was terminated and the remaining debt discount from the warrant valuation was expensed. See Note 12.

COMMON STOCK

9 Months Ended

Sep. 30, 2012

COMMON STOCK

OptimizeRx Corporation has 500,000,000 shares of $.001 par value common stock authorized as of September 30, 2012.

There were 14,232,496 and 14,192,496 common shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively.

On June 30, 2011, the Company entered into a settlement agreement with Midtown Partners. Under the settlement agreement, the Company will pay Midtown Partners $57,500 and grant 100,000 shares of its common stock. The cost of the settlement has been recorded as equity issuance costs. As a result of the settlement, the litigation in the Eastern District of Michigan was dismissed.

During the year ended December 31, 2011, the Company issued 475,820 shares of common stock to satisfy $500,000 of preferred dividends. The Company has not declared any dividends in 2012.

On June 1, 2012, the Company entered into a consulting agreement with North Coast Advisors, Inc. for various services. The Company agreed to issue 40,000 shares of common stock as of the date of the contract. However, these shares were not issued until July 12, 2012. The Company also agrees to issue an additional 40,000 shares every six months in alignment with the agreement renewal up to the two years of the agreement. The first 40,000 shares were valued at the Company’s common stock price as of the date of the contract, which was $1.12/share. Four months of the first period of the contract have been expensed, with the remaining two months recorded as prepaid expenses.

PREFERRED STOCK

9 Months Ended

Sep. 30, 2012

Equity [Abstract]

PREFERRED STOCK

Series A Preferred

During the year ended December 31, 2008, 35 preferred shares were issued for $3,500,000. Issuance costs totaled $515,000 resulting in net proceeds of $2,985,000. The 35 shares are convertible to 3,500,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 6,000,000 shares of common stock at an exercise price of $2 for a period of seven years.

The holders of the preferred stock are entitled to semi-annual dividends payable on the stated value of the Series A preferred stock at a rate of 10% per annum, which shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series A preferred stock shall also be convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1 conversion price.

Series A Preferred Continued

On May 12, 2010, the Company’s Board declared and issued 236,598 common shares as payment for all cumulative and current semi-annual dividends. On November 16, 2010, the Company’s Board declared and issued 173,922 common shares for its semi-annual dividend payment. On March 25, 2011, the Company’s Board declared and issued 176,768 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 156,306 common shares for its semi-annual dividend payment. The Company has undeclared dividends that were due in February and September 2012 totaling $350,000.

Series B Preferred

During the year ended December 31, 2010, 15 preferred shares were issued for $1,500,000. The 15 shares are convertible to 1,500,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 2,000,000 shares of common stock at an exercise price of $3 for a period of seven years.

The preferred stock was issued for $1,500,000 less associated issuance costs of $350,000 for net proceeds of $1,150,000. Additionally, 3,000,000 common stock warrants were issued with the preferred stock. Based on the fair values of the preferred stock and common stock warrants on the issue date, $341,100 was allocated to preferred stock and $1,158,900 was allocated to the common stock warrants. Equity issuance costs of $350,000 were allocated to the preferred stock.

During the quarter ended September 30, 2011, 15 preferred shares were issued to an investor for $1,500,000. The 15 shares are convertible to 1,500,000 shares of common stock and bear a 10% cumulative dividend. In addition, there was a warrant issued to purchase 1,000,000 shares of common stock at an exercise price of $3 for a period of seven years. Based on the fair values of the preferred stock and common stock warrants on the issue date, $855,460 was allocated to preferred stock and $644,540 was allocated to the common stock warrants. See Note 12.

The holders of the preferred stock are entitled to semi-annual dividends payable on the stated value of the Series B preferred stock at a rate of 10% per annum, which shall be cumulative, and accrue daily from the issuance date. The dividends may be paid in cash or shares of the Company's common stock at management’s discretion. If after the conversion eligibility date, the market price for the common stock for any ten consecutive trading days in which the stock trades for over $2 per share and trading exceeds 100,000 shares per day, the preferred shareholders can be required to convert their shares to common stock. Each share of Series B preferred stock shall also be convertible at the option of the holder into that number of shares of common stock of the Company at the stated value of such share at a $1.50 conversion price.

The holder may cause this conversion at the time the shares are eligible for resale by the holder. The conversion price is subject to adjustment as hereinafter provided, at any time, or from time to time upon the terms and in the manner hereinafter set forth in the shareholder agreement. On March 25, 2011, the Company’s Board declared and issued 75,758 common shares for its semi-annual dividend payment. On September 21, 2011, the Company's Board declared and issued 66,988 common shares for its semi-annual dividend payment. The Company has undeclared dividends that were due in February and September 2012 totaling $150,000.

STOCK OPTIONS AND WARRANTS

9 Months Ended

Sep. 30, 2012

STOCK OPTIONS AND WARRANTS

The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values.

The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered.

On October 1, 2010, the Company issued 25,000 stock options to an employee with a vesting period of one year and an exercise price of $1.21. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 241%, risk-free interest rate of 1.26% and expected life of 60 months. The Company recognized share-based compensation expense of $6,203 during the year ended December 31, 2010 with the remaining balance of $18,610 to be recognized in 2011. $6,203 has been recognized in the year ended September December 31, 2011.

On April 27, 2011, the Company issued 100,000 stock options to an individual at an exercise price of $0.73. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 221%, risk-free interest rate of 2.06% and expected life of 60 months. The agreement is for a period of six months. The Company recognized expenses of $83,992 during the year ended December 31, 2011.

On May 31, 2011, the Company issued 285,000 stock options to 3 employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 218%, risk-free interest rate of 1.68% and expected life of 60 months. The total value of the options was $320,585. The options vest over one year. The Company recognized share-based compensation expense of $187,005 during the year ended December 31, 2011. The remaining balance was recognized over the first five months of 2012.

During the quarter ended September 30, 2011, there was a warrant issued to purchase 1,000,000 shares of common stock at an exercise price of $3 for a period of seven years. In addition, 15 preferred shares were issued to an investor for $1,500,000. The 15 shares are convertible to 1,500,000 shares of common stock and bear a 10% cumulative dividend. Based on the fair values of the preferred stock and common stock warrants on the issue date, $855,460 was allocated to preferred stock and $644,540 was allocated to the common stock warrants. See Note 11.

During the quarter ended December 31, 2011, the Company issued 20,000 stock options to 2 employees at an exercise price of $1.00. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 204-205%, risk-free interest rate of 0.88-0.93% and expected life of 60 months. The total value of the options was $19,270. The options vest over one year. The Company recognized share-based compensation expense of $2,480 during the year ended December 31, 2011 and $14,454 during the nine months ended September 30, 2012. The remaining balance will be recognized over the current year.

On November 21, 2011, the Company issued 100,000 stock options to an individual at an exercise price of $0.73. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 205%, risk-free interest rate of 0.92% and expected life of 60 months. The Company recognized expenses of $8,346 during the year ended December 31, 2011 and $75,117 during the nine months ended September 30, 2012. The remaining balance will be recognized over the current year.

During the quarter ended March 31, 2012, the Company issued 50,000 stock options to 4 non-employees at an exercise price of $0.89. The options were valued on the grant date using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, expected volatility of 198%, risk-free interest rate of 0.65% and expected life of 48 months. The total value of the options was $35,091. The options vest over 4 months. The Company recognized share-based compensation expense of $35,091 during the six months ended June 30, 2012.

OPERATING LEASES

9 Months Ended

Sep. 30, 2012

Leases [Abstract]

OPERATING LEASES

The Company signed a lease for new office space on December 1, 2011 at an approximate rent of $5,000 per month. The new offices are in Rochester, Michigan. The lease is for three years with an option to renew for an additional two years at approximately $5,200 per month with six months advance notice to exercise the option.

Minimum annual rent is as follows for the initial term of the lease:

Year ended December 31, 2012	$	60,591
2013		60,591
2014		55,542
2015		0
Total lease commitment	$	176,724

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2012

During the year ended December 31, 2010, the Company acquired from an officer and shareholder the technical contributions and assignment of all exclusive rights to and for the SampleMD patent currently in process in exchange for 300,000 shares of common stock to be granted at the discretion of the seller in addition to 200,000 stock options valued at $360,000. The shares were valued on the grant date at $570,000 and have been recorded as a payable to the related party.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

MAJOR CUSTOMERS

9 Months Ended

Sep. 30, 2012

MAJOR CUSTOMERS

The Company had two major customers that accounted for 50% and one major customer that accounted for 50% of the Company’s revenues for the nine months ended September 30, 2012 and 2011, respectively. The Company expects to continue to maintain these relationships with the customers.

INCOME TAXES

9 Months Ended

Sep. 30, 2012

Income Tax Disclosure [Abstract]

INCOME TAXES

For the nine months ended September 30, 2012, the Company incurred a net loss of approximately $483,000 and therefore has no tax liability. The Company began operations in 2007 and has previous net operating loss carry-forwards of $13,479,000 through December 31, 2011. The cumulative loss of $13,856,000 will be carried forward and can be used through the year 2032 to offset future taxable income. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting.

The provision for Federal income tax consists of the following for the nine months ended September 30, 2012 and 2011:

	2012			2011
Federal income tax benefit attributable to:
Current operations	$	164,000		$	689,000
Valuation allowance		(164,000	)		(689,000	)
Net provision for federal income tax	$	0		$	0

The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of September 30, 2012 and December 31, 2011:

	2012			2011
Deferred tax asset attributable to:
Net operating loss carryover	$	4,747,000		$	4,583,000
Valuation allowance		(4,747,000	)		(4,583,000	)
Net deferred tax asset	$	0		$	0

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $13,856,000 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

OPERATING EXPENSES

9 Months Ended

Sep. 30, 2012

OPERATING EXPENSES

Operating expenses consisted of the following for the three months and nine months ended September 30, 2012 and 2011, respectively:

	Three months ended				Nine months ended
	September 30,				September 30,
	2012		2011 (restated)		2012		2011 (restated)
Advertising	$	1,167	$	149,386	$	45,088	$	455,181
Professional fees		83,235		27,844		155,870		240,733
Consulting		0		51,478		7,835		133,579
Salaries, wages and benefits		299,286		201,585		900,751		611,926
Rent		15,148		7,606		47,214		22,606
Depreciation and amortization		46,735		30,049		140,087		90,149
Stock-based compensation		29,857		0		258,240		0
General and administrative		83,877		132,812		226,172		301,521
Total Operating Expenses	$	559,305	$	600,760	$	1,781,257	$	1,855,695

GOING CONCERN

9 Months Ended

Sep. 30, 2012

GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has sustained substantial losses since inception.

In view of this matter, the ability of the Company to continue as a going concern is dependent upon growth of revenues and the ability of the Company to raise additional capital. Management believes that its successful ability to raise capital and increases in revenues will provide the opportunity for the Company to continue as a going concern.

RESTATEMENT

9 Months Ended

Sep. 30, 2012

Equity [Abstract]

RESTATEMENT

The Company has restated its Consolidated Statement of Operations and its Consolidated Statement of Cash Flows for the three months and nine months ended September 30, 2011 to correct an error in its accounting. The Company did not originally accrue expenses related to advertising, marketing and employee bonuses during that period.

		Nine months ended September 30, 2011
Financial Statement	Line Item		Corrected		Previously Stated
Income statement	Operating expenses		1,855,695		1,445,070
Income statement	Loss from operations		(1,070,085	)	(659,460	)
Income statement	Loss before provision for income taxes		(2,027,619	)	(1,616,994	)
Income statement	Net loss		(2,027,619	)	(1,616,994	)
Statement of cash flows	Net loss		(2,027,619	)	(1,616,994	)
Statement of cash flows	Change in accounts payable		215,731		(9,269	)
Statement of cash flows	Change in accrued expenses		(18,200	)	(63,200	)
Statement of cash flows	Change in prepaid expenses		(24,220	)	(116,405	)

		Three months ended September 30, 2011
Financial Statement	Line Item		Corrected		Previously Stated
Income statement	Operating expenses		600,760		482,635
Income statement	Loss from operations		(409,167	)	(291,042	)
Income statement	Loss before provision for income taxes		(1,087,504	)	(969,379	)
Income statement	Net loss		(1,087,504	)	(969,379	)

Tabular disclosure of the nature and effects of a restatement to correct an error in the reported results of operations of prior periods. When prior period adjustments are recorded, the resulting effects (both gross and net of applicable income tax) on the net income of prior periods are disclosed in the annual report for the year in which the adjustments are made, and amended filings of previously issued reports are typically issued.

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2012

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2012 through the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2012
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Form 10-K filed with the SEC as of and for the year ended December 31, 2011. In the opinion of management, all adjustments necessary for the financial statements to be not misleading for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.
Accounting Basis	Accounting Basis The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting). The Company has adopted a December 31 fiscal year end.
Principles of Consolidation	Principles of Consolidation The financial statements reflect the consolidated results of OptimizeRx Corporation (a Nevada corporation) and its wholly owned subsidiary OptimizeRx Corporation (a Michigan corporation). All material inter-company transactions have been eliminated in the consolidation.
Reclassifications	Reclassifications Certain accounts and financial statement captions in the prior periods have been reclassified to conform to the current period financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the accompanying financial statements, the Company considers all highly liquid instruments with an initial maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of cash, accounts receivable, prepaid expenses, accounts payable, accounts payable – related party, accrued expenses and deferred revenue approximates the carrying amount of these financial instruments due to their short-term nature. The fair value of long-term debt, which approximates its carrying value, is based on current rates at which the Company could borrow funds with similar remaining maturities.
Property and Equipment	Property and Equipment The capital assets are being depreciated over their estimated useful lives, three to seven years using the straight-line method of depreciation for book purposes.
Revenue Recognition	Revenue Recognition All revenue is recognized when it is earned. Revenues are generated either through the Company’s website activities, in which we earn revenue from advertising and lead generation activities, or from our SampleMD activities, which include offering setup within the systems and our offers, coupons, and vouchers that enable our customers to save money on medical products and services. The Company’s processes are monitored by third parties who collect revenues from clients on a per activity basis and report and forward the revenue to the Company’s account.
Income Taxes	Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Research and Development	Research and Development The Company’s key members are part of a continual research development team and monitor new technologies, trends, services and partnerships that can provide the Company with additional services, value to healthcare and pharmaceutical industries and to the patients it serves. The Company seeks to educate team members through understanding of all market dynamics that have the potential to affect the business both short term and longer term. The primary goal is to help patients better afford and access the medicines their doctor prescribes, as well as other healthcare products and services they need. Based on this, the Company continually seeks better ways to meet this mission through technology, better user experiences and new ways to engage industries to provide new support for patients needing their products. The Company is always seeking new services and solutions to offer. At this time, the three current platforms provide robust opportunities and growth during the next five years.
Concentration of Credit Risks	Concentration of Credit Risks The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the depreciable lives of such assets and the allowance for doubtful accounts receivable. Actual results could differ from these estimates.
Earnings Per Common and Common Equivalent Share	Earnings Per Common and Common Equivalent Share The computation of basic earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus common stock equivalents which would arise from the exercise of warrants outstanding using the treasury stock method and the average market price per share during the year. Options, warrants and convertible preferred stock which are common stock equivalents are not included in the diluted earnings per share calculation for June 30, 2012 and 2011, respectively, since their effect is anti-dilutive.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

PREPAID EXPENSES (Tables)

9 Months Ended

Sep. 30, 2012

SCHEDULE OF PREPAID EXPENSES

	2012		2011
Insurance	$	7,257	$	5,937
Website maintenance		0		17,500
Rent		5,049		0
Consulting		31,627		91,811
Employee advances		959		694
Advertising		0		3,090
Total prepaid expenses	$	44,892	$	119,032

PROPERTY AND EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2012

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

	2012			2011
Computer equipment	$	22,360		$	20,130
Furniture and fixtures		11,088			11,088
Subtotal		33,448			31,218
Accumulated depreciation		(11,381	)		(7,287	)
Property and equipment, net	$	22,067		$	23,931

WEBSITE DEVELOPMENT COSTS (Tables)

9 Months Ended

Sep. 30, 2012

WEBSITE DEVELOPMENT COSTS

	2012			2011
OptimizeRx web development	$	154,133		$	154,133
SampleMD web development		602,517			553,877
Subtotal, web development costs		756,650			708,010
Accumulated amortization		(278,393	)		(183,429	)
Impairment		(59,083	)		(59,083	)
Web development costs, net	$	419,174		$	465,498

PATENT RIGHTS AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

PATENT RIGHTS AND INTANGIBLE ASSETS

	2012			2011
Patent rights and intangible assets	$	930,000		$	930,000
Accumulated amortization		(123,088	)		(82,059	)
Patent rights and intangible assets, net	$	806,912		$	847,941

ACCRUED EXPENSES (Tables)

9 Months Ended

Sep. 30, 2012

ACCRUED EXPENSES

	2012		2011
Accrued payroll taxes	$	0	$	0
Accrued bonuses		0		60,000
Accrued audit fees		0		6,000
Total accrued expenses	$	0	$	66,000

OPERATING LEASES (Tables)

9 Months Ended

Sep. 30, 2012

Leases [Abstract]

OPERATING LEASES

Year ended December 31, 2012	$	60,591
2013		60,591
2014		55,542
2015		0
Total lease commitment	$	176,724

INCOME TAXES (Tables)

9 Months Ended

Sep. 30, 2012

Income Tax Disclosure [Abstract]

FEDERAL INCOME TAX

	2012			2011
Federal income tax benefit attributable to:
Current operations	$	164,000		$	689,000
Valuation allowance		(164,000	)		(689,000	)
Net provision for federal income tax	$	0		$	0

DEFERRED TAX ASSET

	2012			2011
Deferred tax asset attributable to:
Net operating loss carryover	$	4,747,000		$	4,583,000
Valuation allowance		(4,747,000	)		(4,583,000	)
Net deferred tax asset	$	0		$	0

OPERATING EXPENSES (Tables)

9 Months Ended

Sep. 30, 2012

RESTATED FINANCIALS FOR SIX MONTHS ENDED

OPERATING EXPENSES

	Three months ended				Nine months ended
	September 30,				September 30,
	2012		2011 (restated)		2012		2011 (restated)
Advertising	$	1,167	$	149,386	$	45,088	$	455,181
Professional fees		83,235		27,844		155,870		240,733
Consulting		0		51,478		7,835		133,579
Salaries, wages and benefits		299,286		201,585		900,751		611,926
Rent		15,148		7,606		47,214		22,606
Depreciation and amortization		46,735		30,049		140,087		90,149
Stock-based compensation		29,857		0		258,240		0
General and administrative		83,877		132,812		226,172		301,521
Total Operating Expenses	$	559,305	$	600,760	$	1,781,257	$	1,855,695

RESTATEMENT (Tables)

9 Months Ended

Sep. 30, 2012

Equity [Abstract]

		Nine months ended September 30, 2011
Financial Statement	Line Item		Corrected		Previously Stated
Income statement	Operating expenses		1,855,695		1,445,070
Income statement	Loss from operations		(1,070,085	)	(659,460	)
Income statement	Loss before provision for income taxes		(2,027,619	)	(1,616,994	)
Income statement	Net loss		(2,027,619	)	(1,616,994	)
Statement of cash flows	Net loss		(2,027,619	)	(1,616,994	)
Statement of cash flows	Change in accounts payable		215,731		(9,269	)
Statement of cash flows	Change in accrued expenses		(18,200	)	(63,200	)
Statement of cash flows	Change in prepaid expenses		(24,220	)	(116,405	)

RESTATED FINANCIALS FOR THREE MONTHS ENDED

		Three months ended September 30, 2011
Financial Statement	Line Item		Corrected		Previously Stated
Income statement	Operating expenses		600,760		482,635
Income statement	Loss from operations		(409,167	)	(291,042	)
Income statement	Loss before provision for income taxes		(1,087,504	)	(969,379	)
Income statement	Net loss		(1,087,504	)	(969,379	)

NATURE OF BUSINESS (Details Narrative)	Apr. 14, 2008 shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Capital stock of OptimizeRx Corporation exchanged for common stock of RFID, Ltd	1,256,958
Ownership of outstanding capital stock of RFID, Ltd.	100.00%

PREPAID EXPENSES - SCHEDULE OF PREPAID EXPENSES (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Notes to Financial Statements
Insurance	$ 7,257	$ 5,937
Website maintenance	0	17,500
Rent	5,049	0
Consulting	31,627	91,811
Employee advances	959	694
Advertising	0	3,090
Total prepaid expenses	$ 44,892	$ 119,032

PROPERTY AND EQUIPMENT - PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Property, Plant and Equipment [Abstract]
Computer equipment	$ 22,360	$ 20,130
Furniture and fixtures	11,088	11,088
Subtotal	33,448	31,218
Accumulated depreciation	(11,381)	(7,287)
Property and equipment, net	$ 22,067	$ 23,931

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	9 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Sep. 30, 2012	Sep. 30, 2011
Property, Plant and Equipment [Abstract]
Depreciation	$ 4,094	$ 1,359

WEBSITE DEVELOPMENT COSTS - WEBSITE DEVELOPMENT COSTS (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2010
Notes to Financial Statements
OptimizeRx web development	$ 154,133	$ 154,133
SampleMD web development	602,517	553,877
Subtotal, web development costs	756,650	708,010
Accumulated amortization	(278,393)	(183,429)
Impairment	(59,083)	(59,083)	$ 59,083
Web development costs, net	$ 419,174	$ 465,498

WEBSITE DEVELOPMENT COSTS (Details Narrative) - USD ($)	9 Months Ended
WEBSITE DEVELOPMENT COSTS (Details Narrative) - USD ($)	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	Dec. 31, 2010
Notes to Financial Statements
Useful Life of Website	5 years
Unamortized Debt Issuance Expense	$ (59,083)	$ (59,083)		$ 59,083
Amortization Expense of Website	$ 94,964		$ 47,761

PATENT RIGHTS AND INTANGIBLE ASSETS - PATENT RIGHTS AND INTANGIBLE ASSETS (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Goodwill and Intangible Assets Disclosure [Abstract]
Patent rights and intangible assets	$ 930,000	$ 930,000
Accumulated amortization	(123,088)	(82,059)
Patent rights and intangible assets, net	$ 806,912	$ 847,941

PATENT RIGHTS AND INTANGIBLE ASSETS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Notes to Financial Statements
Useful life of Patent	17 years
Amortization Expense of Patent	$ 41,029	$ 41,029

ACCRUED EXPENSES - ACCRUED EXPENSES (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Notes to Financial Statements
Accrued payroll taxes	$ 0	$ 0
Accrued bonuses	0	60,000
Accrued audit fees	0	6,000
Total accrued expenses	$ 0	$ 66,000

Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).